(Dexborneol + edaravone) is under clinical development by Neurodawn Pharmaceutical and currently in Phase I for Acute Ischemic Stroke. According to GlobalData, Phase I drugs for Acute Ischemic Stroke have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Dexborneol + edaravone)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Dexborneol + edaravone) overview
Dexborneol and Edaravone (Sanbexin) is a fixed dose combination product, acts as a cerebro protective agent. Sanbexin is indicated for the improvement of neurological symptoms and dysfunction of activities of daily living caused by acute cerebral infarction. It is under development for the treatment of acute ischemic stroke, amyotrophic lateral sclerosis and Intracerebral hemorrhage. It acts by targeting free radical. The drug candidate is administered through sublingual route as a tablet and through parenteral route.
Neurodawn Pharmaceutical overview
Neurodawn Pharmaceutical is engaged in drug development services for the treatment of central nervous system diseases. The company is headquartered in Nanjing, Jiangsu, China.
For a complete picture of (Dexborneol + edaravone)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
